Drugs / ASP4901
last change Apr 2014 re-read 2 minutes ago

ASP4901

Developed for
benign prostatic hyperplasia
Investigated by
Astellas Pharma Inc

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02038868 Jul 2013 → Apr 2014 benign prostatic hyperplasia Astellas Pharma Inc Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ASP4901 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02038868
Route Oral oral dose of ASP4901 once daily for 4 weeks” NCT02038868